Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:BIVI NASDAQ:CALC NASDAQ:SPRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.95$0.83$0.55▼$2.22$11.76M1.48195,180 shs189,908 shsBIVIBioVie$1.52$1.44$1.06▼$12.10$11.46M0.7293,234 shs63,094 shsCALCCalciMedica$0.63$0.63$0.46▼$7.20$9.94M0.85126,540 shs50,065 shsSPRCSciSparc$4.27$4.88$2.98▼$80.10$2.41M2.7144,682 shs19,501 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%+12.40%+2.16%+18.76%-43.11%BIVIBioVie0.00%+11.76%+1.33%+21.60%-85.24%CALCCalciMedica0.00%+1.44%+7.60%+6.59%-65.06%SPRCSciSparc0.00%-2.51%-36.17%-9.42%-92.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.95$0.83$0.55▼$2.22$11.76M1.48195,180 shs189,908 shsBIVIBioVie$1.52$1.44$1.06▼$12.10$11.46M0.7293,234 shs63,094 shsCALCCalciMedica$0.63$0.63$0.46▼$7.20$9.94M0.85126,540 shs50,065 shsSPRCSciSparc$4.27$4.88$2.98▼$80.10$2.41M2.7144,682 shs19,501 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%+12.40%+2.16%+18.76%-43.11%BIVIBioVie0.00%+11.76%+1.33%+21.60%-85.24%CALCCalciMedica0.00%+1.44%+7.60%+6.59%-65.06%SPRCSciSparc0.00%-2.51%-36.17%-9.42%-92.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07328.07% UpsideBIVIBioVie 1.00SellN/AN/ACALCCalciMedica 2.00Hold$10.001,490.08% UpsideSPRCSciSparc 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SPRC, APRE, BIVI, and CALC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BIVIBioVie Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/31/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.003/31/2026APREAprea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $1.203/5/2026CALCCalciMedica OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $10.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K40.56N/AN/A$3.36 per share0.28BIVIBioVieN/AN/AN/AN/A$2.07 per shareN/ACALCCalciMedicaN/AN/AN/AN/A($0.07) per shareN/ASPRCSciSparc$860K2.83N/AN/A$12.93 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)BIVIBioVie-$17.54M-$2.45N/AN/AN/AN/A-101.15%-90.18%N/ACALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)SPRCSciSparc-$12.18MN/AN/AN/AN/AN/AN/AN/AN/ALatest SPRC, APRE, BIVI, and CALC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 million$0.28 million5/11/2026Q3 2026BIVIBioVie-$0.73-$0.70+$0.03-$0.70N/AN/A4/29/2026Q4 2025SPRCSciSparcN/A-$31.6050N/A-$31.6050N/A$0.20 million3/16/2026Q4 2025APREAprea Therapeutics-$0.38-$0.32+$0.06-$0.32N/A$0.00 million3/3/2026Q4 2025CALCCalciMedicaN/A-$0.69N/A-$0.69N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92BIVIBioVieN/A9.969.96CALCCalciMedicaN/A1.611.61SPRCSciSparcN/A2.412.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%BIVIBioVie4.59%CALCCalciMedicaN/ASPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%BIVIBioVie0.90%CALCCalciMedica41.55%SPRCSciSparc1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million10.70 millionNo DataBIVIBioVie107.54 million7.47 millionNo DataCALCCalciMedica3015.80 million9.23 millionNo DataSPRCSciSparc4570,000557,000Not OptionableSPRC, APRE, BIVI, and CALC HeadlinesRecent News About These CompaniesHead to Head Comparison: SciSparc (NASDAQ:SPRC) versus Inotiv (NASDAQ:NOTV)May 21, 2026 | americanbankingnews.comNeurothera Labs Announces Adoption of Semi-Annual ReportingMay 20, 2026 | thenewswire.comTCritical Survey: ProPhase Labs (NASDAQ:PRPH) & SciSparc (NASDAQ:SPRC)May 16, 2026 | americanbankingnews.comSciSparc Regains Conditional Nasdaq Compliance After Equity ShortfallMay 11, 2026 | tipranks.comNeurothera Labs Announces Continuance into OntarioApril 30, 2026 | thenewswire.comTSciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent FilingMarch 16, 2026 | tipranks.comSciSparc Ltd. Reports NeuroThera Labs' Patent Application for Innovative Depression Treatment Combining MEAI and PEAMarch 16, 2026 | quiverquant.comQSciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression TherapyMarch 16, 2026 | globenewswire.comSciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD.March 12, 2026 | quiverquant.comQSciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseMarch 12, 2026 | globenewswire.comSciSparc Ltd. Subsidiary NeuroThera Labs Inc. Enters Share Purchase Agreement to Acquire Majority Stake in CliniQuantum Ltd.March 10, 2026 | quiverquant.comQSciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trailsMarch 10, 2026 | globenewswire.comClearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseMarch 10, 2026 | globenewswire.comSciSparc to Enact 1-for-9 Reverse Share Split as Outstanding Shares ShrinkMarch 2, 2026 | tipranks.comSciSparc Announces 1-for-9 Reverse Share SplitMarch 2, 2026 | globenewswire.comSciSparc Amends $10 Million Note Deal, Issues $2 Million Initial Convertible NoteFebruary 17, 2026 | tipranks.comSciSparc Shareholders Approve February Governance AgendaFebruary 4, 2026 | tipranks.comSciSparc Subsidiary NeuroThera Wins U.S. Patent for Cannabinoid-Based Antimicrobial Resistance PlatformFebruary 2, 2026 | tipranks.comSciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSAFebruary 2, 2026 | globenewswire.comNeurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSAFebruary 2, 2026 | thenewswire.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRC, APRE, BIVI, and CALC Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.95 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.94 -0.01 (-0.53%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.BioVie NASDAQ:BIVI$1.52 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.47 -0.05 (-3.22%) As of 05/22/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.CalciMedica NASDAQ:CALC$0.63 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.64 +0.02 (+2.40%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.SciSparc NASDAQ:SPRC$4.27 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.51 +0.24 (+5.71%) As of 05/22/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
